| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
(R)-Tegoprazan specifically targets the gastric H+/K+-ATPase (proton pump). It acts as a potassium-competitive acid blocker (P-CAB), binding reversibly to the K+-binding site on the pump. In vitro, (R)-Tegoprazan is a potent inhibitor of canine kidney Na+/K+-ATPase with an IC50 of 98 nM. The racemic mixture of Tegoprazan inhibits porcine, canine, and human H+/K+-ATPases in vitro with IC50 values ranging from 0.29 to 0.52 uM.
|
|---|---|
| ln Vitro |
In cell-free enzyme assays, (R)-Tegoprazan (example 3) is a potent inhibitor of gastric H+/K+-ATPase, with an IC50 of 98 nM against canine kidney Na+/K+-ATPase. The racemic mixture of Tegoprazan inhibits porcine H+/K+-ATPase with an IC50 of 0.53 uM in a reversible manner, whereas esomeprazole shows weak and irreversible inhibition with an IC50 of 42.52 uM. Tegoprazan also inhibits canine and human H+/K+-ATPases with IC50 values ranging from 0.29 to 0.52 uM.
|
| ln Vivo |
In vivo, Tegoprazan (the racemate) has been studied in rat models of gastric acid-related disease. It effectively inhibits gastric acid secretion and demonstrates protective effects in models of reflux esophagitis and gastric ulcers. As a potassium-competitive acid blocker, it provides a rapid onset of action and sustained acid suppression compared to conventional proton pump inhibitors. (R)-Tegoprazan may be the more active enantiomer contributing to the overall pharmacological activity of the racemate.
|
| Enzyme Assay |
The in vitro H+/K+-ATPase inhibition assay for (R)-Tegoprazan uses porcine gastric vesicles or canine kidney membrane preparations. Enzyme (10 ug protein) is incubated in buffer containing 10 mM PIPES (pH 6.5), 140 mM KCl, 2 mM MgCl2, and 1 mM ATP. (R)-Tegoprazan is serially diluted (0.01-1000 nM) and added to the reaction. After 30 minutes at 37degC, the reaction is stopped with trichloroacetic acid. Inorganic phosphate (Pi) released is quantified by the malachite green method. The IC50 value (98 nM for canine Na+/K+-ATPase) is calculated from the concentration-response curve using non-linear regression analysis. For H+/K+-ATPase inhibition, the racemic compound Tegoprazan has an IC50 of 0.53 uM.
|
| Cell Assay |
For in vitro cellular assays, isolated rabbit gastric glands are prepared by collagenase digestion. Glands are suspended in HEPES-buffered RPMI 1640 medium and seeded in 24-well plates at 1×10⁵ glands/well. (R)-Tegoprazan (0.001-10 uM) is added to the glands and incubated for 15 minutes, followed by stimulation with 100 uM histamine (or 1 mM dbcAMP) for 60 minutes at 37degC. Acid secretion is measured by the accumulation of [14C]-aminopyrine. The ratio of intracellular to extracellular [14C] is calculated, and EC50 values are derived from dose-response curves.
|
| Animal Protocol |
An in vivo protocol for Tegoprazan uses a rat model of reflux esophagitis. Male SD rats (6-8 weeks old) are fasted for 24 hours. Under anesthesia, the pylorus and forestomach are ligated to induce reflux esophagitis. (R)-Tegoprazan is administered orally by gavage at doses of 0.1-10 mg/kg (formulated in 0.5% methylcellulose) once daily for 4 consecutive days. On day 5, the esophagus is harvested and the area of esophageal mucosal lesions is measured using a dissecting microscope. The percent inhibition of lesion area is calculated relative to the vehicle control group. The ED50 is determined from dose-response curves.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for (R)-Tegoprazan is not widely published. The racemic Tegoprazan has a good oral absorption profile with moderate bioavailability. It is metabolized primarily in the liver via CYP450 enzymes. The terminal half-life of Tegoprazan is approximately 4-6 hours, suitable for once- or twice-daily dosing. Peak plasma concentrations (Cmax) are achieved 1-2 hours post-dose. Plasma protein binding is moderate. Excretion occurs primarily via the biliary/fecal route, with renal elimination playing a minor role.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for (R)-Tegoprazan is not available. Based on the safety profile of the racemic mixture of Tegoprazan, it is generally well-tolerated in preclinical studies. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal pain. Long-term acid suppression may lead to hypergastrinemia and potential enterochromaffin-like cell hyperplasia. Standard toxicology studies have been conducted for Tegoprazan as part of its clinical development program.
|
| References | |
| Additional Infomation |
(R)-Tegoprazan is a research-grade chemical and is not approved for clinical use as a single enantiomer product. Its molecular formula is C20H19F2N3O3 with a molecular weight of 387.38. It is a potent inhibitor of gastric H+/K+-ATPase (IC50 = 98 nM for canine kidney Na+/K+-ATPase). (R)-Tegoprazan is a useful tool for the development of analytical methods and for studying the stereospecific pharmacology of potassium-competitive acid blockers in gastrointestinal diseases.
|
| Molecular Formula |
C20H19F2N3O3
|
|---|---|
| Molecular Weight |
387.38
|
| Exact Mass |
387.139
|
| CAS # |
942195-56-4
|
| PubChem CID |
58900204
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
28
|
| Complexity |
581
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1(C)NC2=C(O[C@H]3C4=C(F)C=C(F)C=C4OCC3)C=C(C(N(C)C)=O)C=C2N=1
|
| InChi Key |
CLIQCDHNPDMGSL-OAHLLOKOSA-N
|
| InChi Code |
InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m1/s1
|
| Chemical Name |
7-[[(4R)-5,7-difluoro-3,4-dihydro-2H-chromen-4-yl]oxy]-N,N,2-trimethyl-3H-benzimidazole-5-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5814 mL | 12.9072 mL | 25.8144 mL | |
| 5 mM | 0.5163 mL | 2.5814 mL | 5.1629 mL | |
| 10 mM | 0.2581 mL | 1.2907 mL | 2.5814 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
